Trials / Completed
CompletedNCT05045716
A Study of Subcutaneous Lecanemab in Healthy Participants
An Open-label, Parallel-group, Randomized Study to Evaluate the Absolute Bioavailability of Single Dose Subcutaneous Administration of Lecanemab in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to determine the absolute bioavailability and pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously (SC) in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lecanemab | Lecanemab IV infusion. |
| DRUG | Lecanemab | Lecanemab SC injection. |
Timeline
- Start date
- 2021-09-07
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
- First posted
- 2021-09-16
- Last updated
- 2022-01-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05045716. Inclusion in this directory is not an endorsement.